Sivik Global Healthcare LLC bought a new stake in Smith & Nephew plc (NYSE:SNN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 190,000 shares of the medical equipment provider's stock, valued at approximately $5,183,000. Smith & Nephew comprises about 2.2% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 28th biggest position.
Several other hedge funds also recently modified their holdings of SNN. Scharf Investments LLC boosted its stake in Smith & Nephew by 20.5% during the 4th quarter. Scharf Investments LLC now owns 2,980,334 shares of the medical equipment provider's stock worth $81,304,000 after acquiring an additional 506,474 shares during the last quarter. American Century Companies Inc. boosted its stake in Smith & Nephew by 343.5% during the 3rd quarter. American Century Companies Inc. now owns 2,364,037 shares of the medical equipment provider's stock worth $58,557,000 after acquiring an additional 1,830,965 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in Smith & Nephew by 56.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 649,795 shares of the medical equipment provider's stock worth $16,095,000 after acquiring an additional 235,658 shares during the last quarter. Clark Estates Inc. NY boosted its stake in Smith & Nephew by 83.3% during the 3rd quarter. Clark Estates Inc. NY now owns 550,000 shares of the medical equipment provider's stock worth $13,624,000 after acquiring an additional 250,000 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Smith & Nephew by 133.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 539,491 shares of the medical equipment provider's stock worth $13,363,000 after acquiring an additional 308,559 shares during the last quarter. Institutional investors own 25.64% of the company's stock.
Smith & Nephew Stock Down 1.9 %
SNN traded down $0.47 during trading on Tuesday, reaching $24.14. The company had a trading volume of 1,173,586 shares, compared to its average volume of 998,784. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.77 and a quick ratio of 0.72. Smith & Nephew plc has a 12 month low of $21.52 and a 12 month high of $32.81. The business's fifty day moving average price is $25.83 and its 200 day moving average price is $26.02. The company has a market cap of $10.55 billion, a P/E ratio of 11.60, a PEG ratio of 1.32 and a beta of 0.73.
Smith & Nephew Announces Dividend
The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Tuesday, April 2nd will be issued a $0.462 dividend. The ex-dividend date of this dividend is Monday, April 1st. This represents a dividend yield of 2.8%. Smith & Nephew's dividend payout ratio (DPR) is presently 43.27%.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy".
Get Our Latest Stock Report on Smith & Nephew
Smith & Nephew Company Profile
(
Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
